Table 1 |.
Description of pediatric CureGN patients with PROMIS data at enrollment
| Variables | All | MCD | FSGS | MN | IgAN | IgAV |
|---|---|---|---|---|---|---|
| N (%) | 478 (100) | 134 (28) | 115 (24) | 28 (6) | 126 (26) | 75 (16) |
| Median age, yr (IQR) | 13 (10–15) | 12 (9–14) | 14 (12–16) | 15 (13–16) | 14 (11–16) | 12 (9–14) |
| Female, n (%) | 202 (42) | 58 (43) | 55 (48) | 16 (57) | 48 (38) | 25 (33) |
| Race, n (%) | ||||||
| Black/African American | 92 (19) | 35 (26) | 43 (37) | 8 (29) | 4 (3) | 2 (3) |
| White/Caucasian | 319 (67) | 77 (57) | 59 (51) | 15 (54) | 103 (82) | 65 (87) |
| Other | 67 (14) | 22 (16) | 13 (11) | 5 (18) | 19 (15) | 8 (11) |
| Hispanic, n (%) | 49 (10) | 12 (9) | 12 (10) | 6 (21) | 14 (11) | 5 (7) |
| Obese, n (%) | 142 (30) | 33 (25) | 42 (37) | 13 (46) | 29 (23) | 25 (33) |
| Hematuria, n (%) | 137 (29) | 13 (10) | 6 (5) | 2 (7) | 89 (71) | 27 (36) |
| Any edema, n (%) | 152 (32) | 54 (40) | 40 (35) | 17 (61) | 22 (17) | 19 (25) |
| Median UP:C (IQR) | 0.5 (0.1–2.2) | 0.4 (0.1–2.7) | 1.2 (0.2–2.8) | 3.2 (0.9–7.4) | 0.3 (0.1–0.8) | 0.5 (0.2–1.4) |
| <0.3, n (%) | 170 (36) | 55 (41) | 31 (27) | 3 (11) | 55 (44) | 26 (35) |
| 0.3–1.5, n (%) | 129 (27) | 25 (19) | 27 (23) | 7 (25) | 41 (33) | 29 (39) |
| 1.5–3.5, n (%) | 55 (12) | 15 (11) | 19 (17) | 3 (11) | 12 (10) | 6 (8) |
| >3.5, n (%) | 76 (16) | 24 (18) | 20 (17) | 13 (46) | 9 (7) | 10 (13) |
| Missing, n (%) | 48 (10) | 15 (11) | 18 (16) | 2 (7) | 9 (7) | 4 (5) |
| Median eGFR (IQR) | 97 (82–116) | 111 (93–127) | 90 (60–108) | 97 (87–114) | 94 (81–109) | 101 (90–121) |
| <30, n (%) | 15 (3) | 1 (1) | 10 (9) | 1 (4) | 2 (2) | 1 (1) |
| 30–60, n (%) | 26 (5) | 6 (4) | 16 (14) | 1 (4) | 3 (2) | |
| 60–90, n (%) | 116 (24) | 19 (14) | 26 (23) | 7 (25) | 46 (37) | 18 (24) |
| >90, n (%) | 294 (62) | 98 (73) | 55 (48) | 18 (64) | 69 (55) | 54 (72) |
| Missing, n (%) | 25 (5) | 10 (7) | 6 (5) | 1 (4) | 6 (5) | 2 (3) |
| IST within 60 days, n (%) | ||||||
| None | 345 (72) | 90 (67) | 81 (70) | 16 (57) | 107 (85) | 51 (68) |
| Corticosteroids alone | 75 (16) | 22 (16) | 16 (14) | 5 (18) | 16 (13) | 16 (21) |
| Other IST | 58 (12) | 22 (16) | 18 (16) | 7 (25) | 3 (2) | 8 (11) |
| Past 60 days median prednisone dose, mg/kg/d (IQR) | 0.2 (0.1–0.5) | 0.2 (0.1–0.5) | 0.1 (0.1–0.3) | 0.2 (0.1–0.5) | 0.4 (0.1–0.7) | 0.3 (0.2–0.5) |
| IST type, n (%) | ||||||
| Corticosteroids | 105 (22) | 31 (23) | 25 (22) | 10 (36) | 17 (13) | 22 (29) |
| CNI | 35 (7) | 15 (11) | 11 (10) | 7 (25) | 1 (1) | 1 (1) |
| Cyclophosphamide | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| Mycophenolate | 19 (4) | 5 (4) | 6 (5) | 0 (0) | 2 (2) | 6 (8) |
| Rituximab | 8 (2) | 4 (3) | 4 (3) | 0 (0) | 0 (0) | 0 (0) |
| Median disease duration, mo (IQR) | 18 (5–42) | 34 (13–61) | 18 (6–45) | 6 (1–17) | 15 (4–34) | 9 (3–20) |
CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; IQR, interquartile range; IST, immunosuppressive therapy; MCD, minimal change disease; MN, membranous nephropathy; UP:C, urinary protein: creatinine ratio.